Related Experiment Video
Updated: Jun 15, 2026
06:41
Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors
Published on: October 20, 2023
[Preparation and identification of recombinant PTD-maxadilan]
Le Zeng1, Rongjie Yu, Mingfang Xu
1Bioengineering Institute of Jinan University, Guangzhou 510632, China.
Summary
A novel fusion protein, PTD-maxadilan (PTD-MAX), was engineered to efficiently cross the blood-brain barrier (BBB). This PTD-MAX demonstrated enhanced inhibitory effects on food intake compared to maxadilan alone.
Area of Science:
- Biotechnology
- Neuroscience
- Protein Engineering
Background:
- The blood-brain barrier (BBB) poses a significant challenge for delivering therapeutic agents to the central nervous system.
- Maxadilan, a peptide, has shown potential but requires efficient BBB penetration.
Purpose of the Study:
- To construct and characterize a novel fusion protein, PTD-maxadilan (PTD-MAX), designed for enhanced BBB permeability.
- To evaluate the in vivo efficacy of PTD-MAX in inhibiting food intake.
Main Methods:
- Synthesized and cloned the PTD-MAX gene into an expression vector.
- Expressed and purified the PTD-MAX fusion protein using an Intein Mediated Purification system in E. coli.
- Determined the molecular weight of PTD-MAX using laser flight mass spectrometry.
- Assessed PTD-MAX BBB penetration and effects on food intake in vivo.
Main Results:
- Successfully constructed and purified the PTD-MAX fusion protein with verified molecular weight.
- In vivo studies confirmed that PTD-MAX can permeate the BBB.
- PTD-MAX exhibited significantly greater inhibitory effects on food intake compared to maxadilan (P<0.05).
Conclusions:
- The engineered PTD-MAX protein effectively crosses the BBB.
- PTD-MAX shows promise as a therapeutic agent for modulating appetite through central mechanisms.
- This work provides a foundation for further applications of PTD-MAX in neuroscience and related fields.
